Dupixent approved in the US as the first-ever biologic medicine …
WEB3 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEB3 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 ... - Sanofi
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
Press Release: Update on FDA priority review of Dupixent for ... - Sanofi
WEBMay 31, 2005 · Sanofi and Regeneron are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible.
Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD …
WEBFeb 23, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Second positive Phase 3 trial for Dupixent® | Sanofi
WEBNov 27, 2006 · The second Dupixent ® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB2 days ago · In July 2024, Regeneron and Sanofi announced the European Commission approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies...